Praxis jumps as movement disorder drug meets trial goals

Praxis Precision Medicines

16/10/2025 12:29

** Drug developer Praxis Precision Medicines' PRAX.O shares surge 90.2% to $109.09 premarket

** Co says its experimental movement disorder drug ulixacaltamide met the main goals of two late-stage studies for essential tremor

** Essential tremor causes involuntary shaking, often in hands, disrupting daily tasks

** Patients on drug showed improved functioning and maintained the effect over time - PRAX

** Co says no drug-related serious side effects; most common were dizziness, brain fog

** Up to last close, stock was down ~25% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.pandey@thomsonreuters.com))